Vivimed Labs (NSE:VIVIMEDLAB) Other Current Payables: ₹0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:VIVIMEDLAB Vivimed Labs Ltd NSE:VIVIMEDLAB
34 GF Score
Price ₹5.04
GF Value ₹2.45
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Vivimed Labs Other Current Payables?

Vivimed Labs NSE:VIVIMEDLAB +1.20% 34 Other Current Payables is ₹0.0 Mil as of Mar. 2026. GuruFocus rates NSE:VIVIMEDLAB with a GF Score™ of 34/100 and a GF Value™ of ₹2.45 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Vivimed Labs's Other Current Payables for the quarter that ended in Mar. 2026 was ₹0.0 Mil.

Vivimed Labs's quarterly Other Current Payables stayed the same from Sep. 2025 (₹0.0 Mil) to Dec. 2025 (₹0.0 Mil) but then increased from Dec. 2025 (₹0.0 Mil) to Mar. 2026 (₹0.0 Mil).

Vivimed Labs's annual Other Current Payables declined from Mar. 2024 (₹161.9 Mil) to Mar. 2025 (₹111.2 Mil) and declined from Mar. 2025 (₹111.2 Mil) to Mar. 2026 (₹0.0 Mil).

Vivimed Labs Other Current Payables Related Terms

Vivimed Labs Other Current Payables Historical Data

* Premium members only.

The historical data trend for Vivimed Labs's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivimed Labs Other Current Payables Chart

Vivimed Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 89.33 164.53 161.92 111.23 0.00

Vivimed Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 111.23 0.00 0.00 0.00 0.00
NSE:VIVIMEDLAB
34GF Score
Vivimed Labs Ltd NSE:VIVIMEDLAB
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivimed Labs Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of ₹0.0 Mil mean?
Vivimed Labs (NSE:VIVIMEDLAB) has a Other Current Payables of ₹0.0 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Vivimed Labs and its competitors.
Is Vivimed Labs' Other Current Payables too high?
Vivimed Labs' current Other Current Payables is ₹0.0 Mil. Overall, Vivimed Labs has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' Other Current Payables compare to ZTS?
Vivimed Labs' Other Current Payables of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Vivimed Labs and its competitors. Vivimed Labs's current Other Current Payables is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.45, compared to a current price of ₹5.04 — trading 105.7% above its estimated fair value. The current Other Current Payables is ₹0.0 Mil. Vivimed Labs' overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current Other Current Payables is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued. The current stock price of ₹5.04 is trading 105.7% above its estimated GF Value™ of ₹2.45. GuruFocus considers Vivimed Labs to be Significantly Overvalued.

Key valuation signals for NSE:VIVIMEDLAB:

  • Other Current Payables: ₹0.0 Mil
  • GF Value™: ₹2.45 vs. price of ₹5.04 (105.7% above fair value)
  • GF Score™: 34/100 with 6 warning signs

No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivimed Labs Business Description

Other Exchanges 532660:India
Address Green Lands, Beside The Plaza Hotel, D.No. 6-3-866/1/G1, 3rd & 4th Floor, GMR Towers, Begumpet, Hyderabad, TG, IND, 500016
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
34GF Score

Get the complete analysis for NSE:VIVIMEDLAB

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5.04
Price
₹2.45
GF Value